DC-PrecisionCancerTherapy

Antibody-Drug Conjugates

Precision Cancer Therapy Driving Investment and Innovation Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative force in precision medicine, revolutionizing cancer treatment by combining the targeting precision of monoclonal…
READ MORE
Navigating the Complexities of PRVs in the Context of AA Withdrawals

Navigating the Complexities of Priority Review Vouchers in the Context of Accelerated Approval Withdrawals

Executive Summary – The FDA’s Accelerated Approval (AA) pathway has been instrumental inexpediting treatments for serious conditions, but recent scrutiny,…
READ MORE
Recent Facts & Figures related to Priority Review Vouchers Value - 2020 to 2024

Recent Facts & Figures related to Priority Review Vouchers Value – 2020 to 2024

Executive Summary – As the year draws to a close, we present an updated analysis of the Priority Review Vouchers…
READ MORE
European Pharma Group Proposes TEE Voucher System to Revitalize Antibiotics R&D

European Pharma Group Proposes TEE Voucher System to Revitalize Antibiotics R&D

Executive Summary – The European pharmaceutical industry is advocating for the implementation of a Transferable Exclusivity Extension (TEE) system to…
READ MORE
KYBORA Advises Xbrane on Global Licensing Agreement with Intas

KYBORA Advises Xbrane on Global Licensing Agreement with Intas

KYBORA, a leading global advisory firm specializing in biopharma transactions, served as the exclusiveadvisor to Xbrane Biopharma AB (Nasdaq Stockholm:…
READ MORE
Navigating Priority Review Voucher Eligibility: Beyond Rare Pediatric Disease Designation

Navigating Priority Review Voucher Eligibility: Beyond Rare Pediatric Disease Designation

Executive Summary – A pediatric drug can qualify for a Priority Review Voucher (PRV) upon FDAapproval, even without receiving a…
READ MORE
Banner

Understanding the Role of the Not Same Active Moiety Principle in RPDD and PRV Evaluations

Executive Summary – The FDA’s “not same active moiety” principle plays a key role in evaluating eligibility for Rare Pediatric…
READ MORE
The latest trends on biotech companies with negative enterprise values

The Latest Trends on Biotech Companies with Negative Enterprise Values: Insights and Implications

In the post Covid era, the spotlight turned sharply towards biotech companies with negative enterprise value (EV). While many saw…
READ MORE
KYBORA Advises Lupin

KYBORA Advises Lupin on the Divestiture of U.S. Commercial Women’s Health Specialty Business to Evofem

Global pharma major Lupin announced that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, a U.S.…
READ MORE
Foundation Rwanda

KYBORA’s Charitable Work

The Stories of Second-Generation Survivors: Meet Intare As Rwanda marks 30 years since the genocide against the Tutsi, we are…
READ MORE

Join KYBORA at BIO 2024

Join KYBORA at BIO 2024! The BIO International Convention, this year held in San Diego, is the largest biotechnology event…
READ MORE

Foundation Rwanda Update

KYBORA's Charitable Work Intare R., a second-generation survivor and Foundation Rwanda Ambassador, has shed light on the ongoing challenges faced…
READ MORE

KYBORA’s Charitable Work

The Foundation Rwanda - KYBORA Initiative Progress Report KYBORA is proud to be working with Foundation Rwanda on a program…
READ MORE

TYPE & ENTER: